Functional Mapping of AKT Signaling and Biomarkers of Response from the FAIRLANE Trial of Neoadjuvant Ipatasertib plus Paclitaxel for Triple-Negative Breast Cancer.
Zhen ShiJulia WulfkuhleMalgorzata NowickaRosa I GallagherCristina SauraPaolo G NuciforoIsabel CalvoJay AndersenJosé Luis Passos-CoelhoJuan Miguel Gil-GilBegoña BermejoDebra A PrattEva Ciruelos GilPatricia VillagrasaMatthew J WongchenkoEmanuel F PetricoinMafalda OliveiraSteven Jay IsakoffPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We showed that the high baseline pAKT levels are associated with the alterations of PI3K/AKT pathway components and enriched benefit of ipatasertib in TNBC.